Correlation of CTNNB1 mutation status with progression arrest rate in RECIST progressive desmoid-type fibromatosis treated with imatinib: translational research results from a phase 2 study of the German Interdisciplinary Sarcoma Group (GISG-01)
Background: CTNNB1 gene mutations are the molecular key events in the majority of sporadic desmoid-type fibromatosis (DF). The specific S45F mutation has been reported to be associated with a more aggressive clinical course in DF. For the current study, the CTNNB1 mutation status was analyzed in DF...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
9 February 2016
|
| In: |
Annals of surgical oncology
Year: 2016, Jahrgang: 23, Heft: 6, Pages: 1924-1927 |
| ISSN: | 1534-4681 |
| DOI: | 10.1245/s10434-016-5132-4 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1245/s10434-016-5132-4
|
| Verfasserangaben: | Bernd Kasper, MD, PhD, Viktor Gruenwald, MD, PhD, Peter Reichardt, MD, Sebastian Bauer, MD, PhD, Peter Hohenberger, MD, PhD, and Florian Haller, MD, PhD |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1667628100 | ||
| 003 | DE-627 | ||
| 005 | 20220816172858.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190618s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1245/s10434-016-5132-4 |2 doi | |
| 035 | |a (DE-627)1667628100 | ||
| 035 | |a (DE-599)KXP1667628100 | ||
| 035 | |a (OCoLC)1341228343 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kasper, Bernd |d 1974- |e VerfasserIn |0 (DE-588)12274764X |0 (DE-627)082130736 |0 (DE-576)29340447X |4 aut | |
| 245 | 1 | 0 | |a Correlation of CTNNB1 mutation status with progression arrest rate in RECIST progressive desmoid-type fibromatosis treated with imatinib |b translational research results from a phase 2 study of the German Interdisciplinary Sarcoma Group (GISG-01) |c Bernd Kasper, MD, PhD, Viktor Gruenwald, MD, PhD, Peter Reichardt, MD, Sebastian Bauer, MD, PhD, Peter Hohenberger, MD, PhD, and Florian Haller, MD, PhD |
| 264 | 1 | |c 9 February 2016 | |
| 300 | |a 4 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 18.06.2019 | ||
| 520 | |a Background: CTNNB1 gene mutations are the molecular key events in the majority of sporadic desmoid-type fibromatosis (DF). The specific S45F mutation has been reported to be associated with a more aggressive clinical course in DF. For the current study, the CTNNB1 mutation status was analyzed in DF samples from the prospective German Interdisciplinary Sarcoma Group (GISG) phase 2 study evaluating imatinib to induce progression arrest in DF Response Evaluation Criteria In Solid Tumors (RECIST) progressive patients. Methods: Thirty-seven patients were treated with a planned dose of imatinib 800 mg daily over 2 years (NCT01137916). The progression arrest rate (PAR) after 6 months of treatment was the primary endpoint of the study. CTNNB1 exon 3 mutation status was analyzed using Sanger sequencing. Results: Thirty-three (97 %) of 34 patients reaching the primary endpoint were evaluable for CTNNB1 mutation exon 3 status. T41A mutations accounted for 30.3 % of the study samples and S45 mutations for 48.5 %, whereas CTNNB1 wild-type status was found in 21.2 %. The respective PAR at 6 months was 70, 81, and 43 %. Patients harboring CTNNB1 mutations demonstrated a higher PAR compared to wild-type DF. There was a statistically significant difference comparing patients with S45F mutations (85 % PAR) versus wild-type status (p = 0.05). Conclusions: Mutations at position S45 were overrepresented in the GISG-01 trial recruiting RECIST progressive patients only. The positive correlation of CTNNB1 mutation status with the progression arrest rate after imatinib therapy supports the idea of a potential predictive impact of the mutation status on DF treatment decision making. | ||
| 650 | 4 | |a Desmoid Tumor | |
| 650 | 4 | |a Imatinib | |
| 650 | 4 | |a Meloxicam | |
| 650 | 4 | |a Pazopanib | |
| 650 | 4 | |a Sorafenib | |
| 700 | 1 | |a Hohenberger, Peter |d 1953- |e VerfasserIn |0 (DE-588)1025311469 |0 (DE-627)72202875X |0 (DE-576)370195574 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of surgical oncology |d Berlin [u.a.] : Springer, 1994 |g 23(2016), 6, Seite 1924-1927 |h Online-Ressource |w (DE-627)343969947 |w (DE-600)2074021-9 |w (DE-576)099879212 |x 1534-4681 |7 nnas |a Correlation of CTNNB1 mutation status with progression arrest rate in RECIST progressive desmoid-type fibromatosis treated with imatinib translational research results from a phase 2 study of the German Interdisciplinary Sarcoma Group (GISG-01) |
| 773 | 1 | 8 | |g volume:23 |g year:2016 |g number:6 |g pages:1924-1927 |g extent:4 |a Correlation of CTNNB1 mutation status with progression arrest rate in RECIST progressive desmoid-type fibromatosis treated with imatinib translational research results from a phase 2 study of the German Interdisciplinary Sarcoma Group (GISG-01) |
| 856 | 4 | 0 | |u https://doi.org/10.1245/s10434-016-5132-4 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190618 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 1025311469 |a Hohenberger, Peter |m 1025311469:Hohenberger, Peter |d 60000 |d 65500 |e 60000PH1025311469 |e 65500PH1025311469 |k 0/60000/ |k 1/60000/65500/ |p 5 | ||
| 998 | |g 12274764X |a Kasper, Bernd |m 12274764X:Kasper, Bernd |d 60000 |d 65500 |e 60000PK12274764X |e 65500PK12274764X |k 0/60000/ |k 1/60000/65500/ |p 1 |x j | ||
| 999 | |a KXP-PPN1667628100 |e 3488302652 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"eki":["1667628100"],"doi":["10.1245/s10434-016-5132-4"]},"physDesc":[{"extent":"4 S."}],"note":["Gesehen am 18.06.2019"],"relHost":[{"part":{"issue":"6","pages":"1924-1927","extent":"4","year":"2016","text":"23(2016), 6, Seite 1924-1927","volume":"23"},"language":["eng"],"title":[{"title_sort":"Annals of surgical oncology","title":"Annals of surgical oncology","subtitle":"the official journal of the Society of Surgical Oncology"}],"pubHistory":["1.1994 -"],"origin":[{"publisherPlace":"Berlin [u.a.] ; Philadelphia, Pa.","dateIssuedDisp":"1994-","publisher":"Springer ; Lippincott Williams & Wilkins","dateIssuedKey":"1994"}],"recId":"343969947","type":{"bibl":"periodical","media":"Online-Ressource"},"corporate":[{"display":"Society of Surgical Oncology","role":"isb"}],"note":["Gesehen am 26.09.25"],"disp":"Correlation of CTNNB1 mutation status with progression arrest rate in RECIST progressive desmoid-type fibromatosis treated with imatinib translational research results from a phase 2 study of the German Interdisciplinary Sarcoma Group (GISG-01)Annals of surgical oncology","id":{"zdb":["2074021-9"],"issn":["1534-4681"],"eki":["343969947"]},"physDesc":[{"extent":"Online-Ressource"}]}],"recId":"1667628100","origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"9 February 2016"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"person":[{"display":"Kasper, Bernd","given":"Bernd","role":"aut","family":"Kasper"},{"display":"Hohenberger, Peter","role":"aut","given":"Peter","family":"Hohenberger"}],"name":{"displayForm":["Bernd Kasper, MD, PhD, Viktor Gruenwald, MD, PhD, Peter Reichardt, MD, Sebastian Bauer, MD, PhD, Peter Hohenberger, MD, PhD, and Florian Haller, MD, PhD"]},"title":[{"title_sort":"Correlation of CTNNB1 mutation status with progression arrest rate in RECIST progressive desmoid-type fibromatosis treated with imatinib","subtitle":"translational research results from a phase 2 study of the German Interdisciplinary Sarcoma Group (GISG-01)","title":"Correlation of CTNNB1 mutation status with progression arrest rate in RECIST progressive desmoid-type fibromatosis treated with imatinib"}],"language":["eng"]} | ||
| SRT | |a KASPERBERNCORRELATIO9201 | ||